Latest news with #DYNE-101
Yahoo
13 hours ago
- Business
- Yahoo
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomorrow, June 17, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne's website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To view the live webcast and replay, please visit About Dyne Therapeutics Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit and follow us on X, LinkedIn and Facebook. Contacts:InvestorsMia Tobiasir@ 781-317-0353 MediaStacy Nartkersnartker@ 781-317-1938
Yahoo
12-03-2025
- Business
- Yahoo
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating
BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price target, suggesting a strong upside from the company's current share price of $12.03. Warning! GuruFocus has detected 3 Warning Signs with DYN. Using its TfR1-targeted delivery system, Dyne focuses in creating therapies for neuromuscular disorders. Key clinical initiatives of the business include its myotonic dystrophy type 1 therapy, now in Phase I/II studies, and its Duchenne muscular dystrophy treatment, which might be commercialized by 2026. The FDA's ruling on Dyne's DM1 therapy is a main determinant of her market course. The date of clearance might affect its capacity to access the market in relation to Avidity, a rival company in the field. Analysts advise Dyne may set itself apart by providing a therapy with advantages for central nervous systems. With a current ratio of 15.6 and a market capitalization of $1.37 billion, the firm shows good liquidity. With a beta of 1.11, it has only little connection with the larger market. Some analysts see a possible buying chance in the stock as it has down 51.19% year to date. Important forthcoming events include possibly accelerated approval applications for DYNE-251 and DYNE-101 in 2026. Early January 2025 will also include results from the DM1 Phase 1/2 ACHIEVE study, which will offer information on functional outcomes and splicing repair. Investor mood is still divided; substantial upward potential depends on clinical benchmarks and regulatory clearance routes. Although concerns still relate to regulatory choices and competitive market positioning, analysts stress the company's strong liquidity and pipeline developments. This article first appeared on GuruFocus. Sign in to access your portfolio
